Risk of rebound hypertension, especially in patients not transitioned from clevidipine to oral antihypertensive therapy after prolonged infusions, should be monitored for at least eight hours ...

There have been several reported cases of rebound hypertension, and the mechanism of this phenomenon is unknown. However, NO release from cultured endothelial cells has been shown to function as a ...

Keros shares have lost more than 60% year-to-date, but retail investors appear undeterred for now, speculating on a potential rebound fueled by its long-term opportunities. For updates and ...